Published in Neurotherapeutics on July 01, 2008
Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci (2011) 2.60
The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem (2011) 1.63
Misfolded proteins in Alzheimer's disease and type II diabetes. Chem Soc Rev (2011) 1.45
Copper in the brain and Alzheimer's disease. J Biol Inorg Chem (2009) 1.40
Design of small molecules that target metal-A{beta} species and regulate metal-induced A{beta} aggregation and neurotoxicity. Proc Natl Acad Sci U S A (2010) 1.37
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Dietary zinc supplementation of 3xTg-AD mice increases BDNF levels and prevents cognitive deficits as well as mitochondrial dysfunction. Cell Death Dis (2010) 1.11
Low levels of copper disrupt brain amyloid-β homeostasis by altering its production and clearance. Proc Natl Acad Sci U S A (2013) 1.11
The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS One (2012) 1.02
Link between Aluminum and the Pathogenesis of Alzheimer's Disease: The Integration of the Aluminum and Amyloid Cascade Hypotheses. Int J Alzheimers Dis (2011) 1.01
Current therapeutic targets for the treatment of Alzheimer's disease. Expert Rev Neurother (2010) 0.99
The role of intracellular zinc release in aging, oxidative stress, and Alzheimer's disease. Front Aging Neurosci (2014) 0.98
8-Hydroxyquinolines: a review of their metal chelating properties and medicinal applications. Drug Des Devel Ther (2013) 0.97
Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species. Inorg Chem (2011) 0.95
Recent Development of Bifunctional Small Molecules to Study Metal-Amyloid-β Species in Alzheimer's Disease. Int J Alzheimers Dis (2010) 0.95
The butyrylcholinesterase K variant confers structurally derived risks for Alzheimer pathology. J Biol Chem (2009) 0.94
Redox control of prion and disease pathogenesis. Antioxid Redox Signal (2010) 0.93
Paradoxical condensation of copper with elevated beta-amyloid in lipid rafts under cellular copper deficiency conditions: implications for Alzheimer disease. J Biol Chem (2009) 0.93
Bivalent ligands targeting multiple pathological factors involved in Alzheimer's disease. ACS Med Chem Lett (2012) 0.91
Pharmacotherapeutic targets in Alzheimer's disease. J Cell Mol Med (2008) 0.91
Association between the c. 2495 A>G ATP7B Polymorphism and Sporadic Alzheimer's Disease. Int J Alzheimers Dis (2011) 0.90
Hypothesis: soluble aβ oligomers in association with redox-active metal ions are the optimal generators of reactive oxygen species in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.90
Mechanism of copper(II)-induced misfolding of Parkinson's disease protein. Sci Rep (2011) 0.89
Nanoprobing of the effect of Cu(2+) cations on misfolding, interaction and aggregation of amyloid β peptide. J Neuroimmune Pharmacol (2012) 0.89
Cu(2+) affects amyloid-β (1-42) aggregation by increasing peptide-peptide binding forces. PLoS One (2013) 0.88
Interactions of metals and Apolipoprotein E in Alzheimer's disease. Front Aging Neurosci (2014) 0.88
Effect of cerebral amyloid angiopathy on brain iron, copper, and zinc in Alzheimer's disease. J Alzheimers Dis (2011) 0.87
Effect of metals on kinetic pathways of amyloid-β aggregation. Biomolecules (2014) 0.87
Prevalent iron metabolism gene variants associated with increased brain ferritin iron in healthy older men. J Alzheimers Dis (2010) 0.86
Computational predictions of volatile anesthetic interactions with the microtubule cytoskeleton: implications for side effects of general anesthesia. PLoS One (2012) 0.86
A prochelator activated by beta-secretase inhibits Abeta aggregation and suppresses copper-induced reactive oxygen species formation. J Am Chem Soc (2010) 0.85
Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease. Rejuvenation Res (2013) 0.84
Metal toxicity at the synapse: presynaptic, postsynaptic, and long-term effects. J Toxicol (2012) 0.83
An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation. ACS Chem Neurosci (2012) 0.82
Spin hamiltonian parameters for Cu(II)-prion peptide complexes from L-band electron paramagnetic resonance spectroscopy. J Am Chem Soc (2011) 0.82
Copper Inhibits NMDA Receptor-Independent LTP and Modulates the Paired-Pulse Ratio after LTP in Mouse Hippocampal Slices. Int J Alzheimers Dis (2011) 0.81
Calorimetric investigation of copper(II) binding to Aβ peptides: thermodynamics of coordination plasticity. J Biol Inorg Chem (2012) 0.81
Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease. Curr Med Chem (2015) 0.81
Comparison of Metal Levels between Postmortem Brain and Ventricular Fluid in Alzheimer's Disease and Nondemented Elderly Controls. Toxicol Sci (2015) 0.80
A potent antioxidant small molecule aimed at targeting metal-based oxidative stress in neurodegenerative disorders. Chem Commun (Camb) (2013) 0.80
Alzheimer's Aβ peptides with disease-associated N-terminal modifications: influence of isomerisation, truncation and mutation on Cu2+ coordination. PLoS One (2010) 0.80
Multifunctional antioxidants for the treatment of age-related diseases. J Med Chem (2010) 0.80
Capturing a reactive state of amyloid aggregates: NMR-based characterization of copper-bound Alzheimer disease amyloid β-fibrils in a redox cycle. J Biol Chem (2014) 0.80
Is Modulation of Oxidative Stress an Answer? The State of the Art of Redox Therapeutic Actions in Neurodegenerative Diseases. Oxid Med Cell Longev (2015) 0.79
Protein misfolding and aggregation in Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol Disord Drug Targets (2014) 0.79
A current view of Alzheimer's disease. F1000 Biol Rep (2009) 0.78
PET neuroimaging studies of [(18)F]CABS13 in a double transgenic mouse model of Alzheimer's disease and nonhuman primates. ACS Chem Neurosci (2015) 0.78
Exploring the reactivity of flavonoid compounds with metal-associated amyloid-β species. Dalton Trans (2012) 0.78
Novel Fluorinated 8-Hydroxyquinoline Based Metal Ionophores for Exploring the Metal Hypothesis of Alzheimer's Disease. ACS Med Chem Lett (2015) 0.77
A Redox-Active, Compact Molecule for Cross-Linking Amyloidogenic Peptides into Nontoxic, Off-Pathway Aggregates: In Vitro and In Vivo Efficacy and Molecular Mechanisms. J Am Chem Soc (2015) 0.77
Zinc and the aging brain. Genes Nutr (2013) 0.77
The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. Front Neurosci (2017) 0.77
Gene Therapy Models of Alzheimer's Disease and Other Dementias. Methods Mol Biol (2016) 0.76
Iron Chelators and Antioxidants Regenerate Neuritic Tree and Nigrostriatal Fibers of MPP+/MPTP-Lesioned Dopaminergic Neurons. PLoS One (2015) 0.76
Hydralazine modifies Aβ fibril formation and prevents modification by lipids in vitro. Biochemistry (2010) 0.76
Monoaminergic neuropathology in Alzheimer's disease. Prog Neurobiol (2016) 0.76
Glutamate-mediated primary somatosensory cortex excitability correlated with circulating copper and ceruloplasmin. Int J Alzheimers Dis (2011) 0.76
Characterization of the internal dynamics and conformational space of zinc-bound amyloid β peptides by replica-exchange molecular dynamics simulations. Eur Biophys J (2013) 0.76
Combining conformational sampling and selection to identify the binding mode of zinc-bound amyloid peptides with bifunctional molecules. J Comput Aided Mol Des (2012) 0.76
Mitochondrial ferritin protects the murine myocardium from acute exhaustive exercise injury. Cell Death Dis (2016) 0.75
Correlative nanoscale 3D imaging of structure and composition in extended objects. PLoS One (2012) 0.75
EPR Methods for Biological Cu(II): L-Band CW and NARS. Methods Enzymol (2015) 0.75
A Bacterial Component to Alzheimer's-Type Dementia Seen via a Systems Biology Approach that Links Iron Dysregulation and Inflammagen Shedding to Disease. J Alzheimers Dis (2016) 0.75
Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal. Drug Discov Today (2016) 0.75
Structure and Synaptic Function of Metal Binding to the Amyloid Precursor Protein and its Proteolytic Fragments. Front Mol Neurosci (2017) 0.75
Investigation of aromatase inhibitory activity of metal complexes of 8-hydroxyquinoline and uracil derivatives. Drug Des Devel Ther (2014) 0.75
Zinc and Copper Differentially Modulate Amyloid Precursor Protein Processing by γ-Secretase and Amyloid-β Peptide Production. J Biol Chem (2017) 0.75
Quercetin Exerts Differential Neuroprotective Effects Against H2O2 and Aβ Aggregates in Hippocampal Neurons: the Role of Mitochondria. Mol Neurobiol (2016) 0.75
The effect of Benzothiazolone-2 on the expression of Metallothionein-3 in modulating Alzheimer's disease. Brain Behav (2017) 0.75
Trehalose Improves Cognition in the Transgenic Tg2576 Mouse Model of Alzheimer's Disease. J Alzheimers Dis (2017) 0.75
The double-edged role of copper in the fate of amyloid beta in the presence of anti-oxidants. Chem Sci (2017) 0.75
Kinetic Analysis Reveals the Identity of Aβ-Metal Complex Responsible for the Initial Aggregation of Aβ in the Synapse. ACS Chem Neurosci (2017) 0.75
Commentary: The Case for Abandoning Therapeutic Chelation of Copper Ions in Alzheimer's Disease. Front Neurol (2017) 0.75
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature (1987) 17.08
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol (1991) 14.25
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell (2005) 8.40
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry (1993) 7.26
Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol (1999) 7.16
Isolation and quantification of soluble Alzheimer's beta-peptide from biological fluids. Nature (1992) 7.02
Neuronal origin of a cerebral amyloid: neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels. EMBO J (1985) 6.24
Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides. Science (1990) 6.03
Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci (2004) 5.37
Rapid induction of Alzheimer A beta amyloid formation by zinc. Science (1994) 5.34
The neurobiology of zinc in health and disease. Nat Rev Neurosci (2005) 5.07
Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol (2001) 4.80
Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron (2001) 4.42
Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci (1998) 4.19
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Aggregation and secondary structure of synthetic amyloid beta A4 peptides of Alzheimer's disease. J Mol Biol (1991) 3.33
Widespread peroxynitrite-mediated damage in Alzheimer's disease. J Neurosci (1997) 3.08
Neurobiology of zinc and zinc-containing neurons. Int Rev Neurobiol (1989) 3.06
RNA oxidation is a prominent feature of vulnerable neurons in Alzheimer's disease. J Neurosci (1999) 2.86
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J Biol Chem (1998) 2.78
The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol (1999) 2.73
Oxidative damage in Alzheimer's. Nature (1996) 2.55
Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet (1991) 2.31
Cu(II) potentiation of alzheimer abeta neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem (1999) 2.30
Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with beta-amyloid deposits in Alzheimer's disease. J Struct Biol (2005) 2.15
The growth inhibitory factor that is deficient in the Alzheimer's disease brain is a 68 amino acid metallothionein-like protein. Neuron (1991) 2.05
Trace amounts of copper in water induce beta-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 2.02
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem (2005) 1.95
Metal binding and oxidation of amyloid-beta within isolated senile plaque cores: Raman microscopic evidence. Biochemistry (2003) 1.89
Longitudinal, quantitative assessment of amyloid, neuroinflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J Neurosci (2007) 1.85
Characterization of copper interactions with alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem (2000) 1.82
Overexpression of Alzheimer's disease amyloid-beta opposes the age-dependent elevations of brain copper and iron. J Biol Chem (2002) 1.74
Characterization of beta-amyloid peptide from human cerebrospinal fluid. J Neurochem (1993) 1.71
Amyloid beta protein enhances the survival of hippocampal neurons in vitro. Science (1989) 1.69
Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc Natl Acad Sci U S A (2002) 1.68
The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci (2005) 1.68
Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem (2001) 1.64
NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci (2005) 1.61
Overexpression of CCS in G93A-SOD1 mice leads to accelerated neurological deficits with severe mitochondrial pathology. Proc Natl Acad Sci U S A (2007) 1.60
Changes in intracellular calcium and glutathione in astrocytes as the primary mechanism of amyloid neurotoxicity. J Neurosci (2003) 1.58
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A (2003) 1.52
Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem (1999) 1.48
Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation. Brain (2006) 1.48
Iron deposits in multiple sclerosis and Alzheimer's disease brains. Brain Res (1997) 1.46
Dietary Cu stabilizes brain superoxide dismutase 1 activity and reduces amyloid Abeta production in APP23 transgenic mice. Proc Natl Acad Sci U S A (2003) 1.46
Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol (1990) 1.43
Histochemically-reactive zinc in amyloid plaques, angiopathy, and degenerating neurons of Alzheimer's diseased brains. Brain Res (2000) 1.42
Metals and Alzheimer's disease. J Alzheimers Dis (2006) 1.39
Elevated cortical zinc in Alzheimer disease. Neurology (2006) 1.38
Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci U S A (2005) 1.34
Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol (2000) 1.31
Copper mediates dityrosine cross-linking of Alzheimer's amyloid-beta. Biochemistry (2004) 1.30
Role of the Menkes copper-transporting ATPase in NMDA receptor-mediated neuronal toxicity. Proc Natl Acad Sci U S A (2006) 1.30
Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem (2006) 1.29
Tyrosine gated electron transfer is key to the toxic mechanism of Alzheimer's disease beta-amyloid. FASEB J (2004) 1.29
Binding of zinc(II) and copper(II) to the full-length Alzheimer's amyloid-beta peptide. J Neurochem (2008) 1.27
Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem (2002) 1.26
Dietary copper and high saturated and trans fat intakes associated with cognitive decline. Arch Neurol (2006) 1.25
Zinc-induced Alzheimer's Abeta1-40 aggregation is mediated by conformational factors. J Biol Chem (1997) 1.24
Copper inhibits beta-amyloid production and stimulates the non-amyloidogenic pathway of amyloid-precursor-protein secretion. Biochem J (1999) 1.24
High-resolution NMR studies of the zinc-binding site of the Alzheimer's amyloid beta-peptide. FEBS J (2007) 1.22
Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem (2004) 1.21
Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med (2002) 1.19
Synaptic release of zinc from brain slices: factors governing release, imaging, and accurate calculation of concentration. J Neurosci Methods (2006) 1.17
Neuronal zinc exchange with the blood vessel wall promotes cerebral amyloid angiopathy in an animal model of Alzheimer's disease. J Neurosci (2004) 1.15
ATP7A (Menkes protein) functions in axonal targeting and synaptogenesis. Mol Cell Neurosci (2007) 1.14
Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem (2004) 1.14
Modulation of A beta adhesiveness and secretase site cleavage by zinc. J Biol Chem (1994) 1.13
Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice. J Neurosci (1999) 1.12
Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. Arch Neurol (2007) 1.10
Engineering metal ion coordination to regulate amyloid fibril assembly and toxicity. Proc Natl Acad Sci U S A (2007) 1.10
Copper-mediated amyloid-beta toxicity is associated with an intermolecular histidine bridge. J Biol Chem (2006) 1.10
Trace copper levels in the drinking water, but not zinc or aluminum influence CNS Alzheimer-like pathology. J Nutr Health Aging (2006) 1.09
The structure of neuritic plaque in the cerebral cortex of aged rats. J Neuropathol Exp Neurol (1981) 1.09
Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem (2006) 1.08
A laser microprobe mass analysis of brain aluminum and iron in dementia pugilistica: comparison with Alzheimer's disease. Eur Neurol (1997) 1.07
Metal ions differentially influence the aggregation and deposition of Alzheimer's beta-amyloid on a solid template. Biochemistry (2007) 1.07
Solution 1H NMR investigation of Zn2+ and Cd2+ binding to amyloid-beta peptide (Abeta) of Alzheimer's disease. Biochim Biophys Acta (2005) 1.06
The galvanization of beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 1.05
Copper depletion down-regulates expression of the Alzheimer's disease amyloid-beta precursor protein gene. J Biol Chem (2004) 1.04
d-penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest (2002) 1.04
Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest (2005) 1.04
Amyloid plaques arise from zinc-enriched cortical layers in APP/PS1 transgenic mice and are paradoxically enlarged with dietary zinc deficiency. Neuroscience (2007) 1.04
Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging (2007) 1.04
Enhanced toxicity and cellular binding of a modified amyloid beta peptide with a methionine to valine substitution. J Biol Chem (2004) 1.04
Correlation of R2 with total iron concentration in the brains of rhesus monkeys. J Magn Reson Imaging (2005) 1.02
BACE1 cytoplasmic domain interacts with the copper chaperone for superoxide dismutase-1 and binds copper. J Biol Chem (2005) 1.02
Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem (2007) 1.01
Metal binding in amyloid beta-peptides shows intra- and inter-peptide coordination modes. Eur Biophys J (2006) 1.01
Radioiodinated clioquinol as a biomarker for beta-amyloid: Zn complexes in Alzheimer's disease. Aging Cell (2006) 1.01
Gene expression profiling in chronic copper overload reveals upregulation of Prnp and App. Physiol Genomics (2004) 1.00
Gene knockout of amyloid precursor protein and amyloid precursor-like protein-2 increases cellular copper levels in primary mouse cortical neurons and embryonic fibroblasts. J Neurochem (2004) 0.99
Association between microdeletion and microduplication at 16p11.2 and autism. N Engl J Med (2008) 19.71
Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet (2007) 14.05
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet (2007) 12.13
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet (2008) 6.71
Chronic traumatic encephalopathy in blast-exposed military veterans and a blast neurotrauma mouse model. Sci Transl Med (2012) 6.27
Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A (2003) 5.44
The genetics of Alzheimer disease: back to the future. Neuron (2010) 4.91
Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. Am J Hum Genet (2008) 4.66
Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci (2008) 4.64
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database. PLoS Genet (2012) 4.27
Depletion of GGA3 stabilizes BACE and enhances beta-secretase activity. Neuron (2007) 3.98
Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol (2003) 3.58
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol (2004) 3.24
Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet (2003) 3.00
Alzheimer's disease: the cholesterol connection. Nat Neurosci (2003) 2.99
The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One (2010) 2.78
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol (2008) 2.54
Iron-export ferroxidase activity of β-amyloid precursor protein is inhibited by zinc in Alzheimer's disease. Cell (2010) 2.46
The inhalation anesthetic isoflurane induces a vicious cycle of apoptosis and amyloid beta-protein accumulation. J Neurosci (2007) 2.42
Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron (2008) 2.30
The common inhalation anesthetic isoflurane induces apoptosis and increases amyloid beta protein levels. Anesthesiology (2006) 2.26
Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron (2010) 2.20
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The genetic epidemiology of neurodegenerative disease. J Clin Invest (2005) 2.08
An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem (2002) 2.00
Metalloenzyme-like activity of Alzheimer's disease beta-amyloid. Cu-dependent catalytic conversion of dopamine, cholesterol, and biological reducing agents to neurotoxic H(2)O(2). J Biol Chem (2002) 1.99
Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease. Lancet (2003) 1.91
The effects of isoflurane and desflurane on cognitive function in humans. Anesth Analg (2011) 1.88
Isoflurane-induced apoptosis: a potential pathogenic link between delirium and dementia. J Gerontol A Biol Sci Med Sci (2006) 1.83
Anesthetics isoflurane and desflurane differently affect mitochondrial function, learning, and memory. Ann Neurol (2012) 1.76
Genome-wide association studies in Alzheimer's disease. Hum Mol Genet (2009) 1.70
The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci (2005) 1.68
The inhalation anesthetic isoflurane increases levels of proinflammatory TNF-α, IL-6, and IL-1β. Neurobiol Aging (2010) 1.62
Magnetic resonance imaging white matter hyperintensities and brain volume in the prediction of mild cognitive impairment and dementia. Arch Neurol (2008) 1.60
Diabetes-associated SorCS1 regulates Alzheimer's amyloid-beta metabolism: evidence for involvement of SorL1 and the retromer complex. J Neurosci (2010) 1.58
PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis (2010) 1.57
The common inhalational anesthetic sevoflurane induces apoptosis and increases beta-amyloid protein levels. Arch Neurol (2009) 1.56
The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res (2004) 1.53
BACE is degraded via the lysosomal pathway. J Biol Chem (2005) 1.53
Alzheimer's disease: one disorder, too many genes? Hum Mol Genet (2004) 1.48
Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate {alpha}-secretase activity. Hum Mol Genet (2009) 1.46
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models". Science (2013) 1.45
Isoflurane-induced caspase-3 activation is dependent on cytosolic calcium and can be attenuated by memantine. J Neurosci (2008) 1.44
Alzheimer's disease and post-operative cognitive dysfunction. Exp Gerontol (2006) 1.41
The inhalation anesthetic desflurane induces caspase activation and increases amyloid beta-protein levels under hypoxic conditions. J Biol Chem (2008) 1.31
No association between CALHM1 and Alzheimer's disease risk. Cell (2008) 1.30
Redox-active metals, oxidative stress, and Alzheimer's disease pathology. Ann N Y Acad Sci (2004) 1.28
The genetics of Alzheimer's disease. Prog Mol Biol Transl Sci (2012) 1.28
Caspase activation increases beta-amyloid generation independently of caspase cleavage of the beta-amyloid precursor protein (APP). J Biol Chem (2003) 1.26
Ubiquilin 1 modulates amyloid precursor protein trafficking and Abeta secretion. J Biol Chem (2006) 1.26
ADAM10 missense mutations potentiate β-amyloid accumulation by impairing prodomain chaperone function. Neuron (2013) 1.25
Assessment of Alzheimer's disease case-control associations using family-based methods. Neurogenetics (2008) 1.23
Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome. PLoS One (2010) 1.23
An AICD-based functional screen to identify APP metabolism regulators. Mol Neurodegener (2007) 1.22
Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J Biol Chem (2007) 1.22
Trace metal contamination initiates the apparent auto-aggregation, amyloidosis, and oligomerization of Alzheimer's Abeta peptides. J Biol Inorg Chem (2004) 1.21
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry (2011) 1.16
Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet (2007) 1.16
Evidence of altered posteromedial cortical FMRI activity in subjects at risk for Alzheimer disease. Alzheimer Dis Assoc Disord (2010) 1.14
Curcumin decreases amyloid-beta peptide levels by attenuating the maturation of amyloid-beta precursor protein. J Biol Chem (2010) 1.14
GAB2 as an Alzheimer disease susceptibility gene: follow-up of genomewide association results. Arch Neurol (2009) 1.13
Copper, beta-amyloid, and Alzheimer's disease: tapping a sensitive connection. Proc Natl Acad Sci U S A (2003) 1.13
Evaluation of the potential excess of statistically significant findings in published genetic association studies: application to Alzheimer's disease. Am J Epidemiol (2008) 1.13
Recovering unused information in genome-wide association studies: the benefit of analyzing SNPs out of Hardy-Weinberg equilibrium. Eur J Hum Genet (2009) 1.12
Generation of the beta-amyloid peptide and the amyloid precursor protein C-terminal fragment gamma are potentiated by FE65L1. J Biol Chem (2003) 1.12
TREM2 and neurodegenerative disease. N Engl J Med (2013) 1.12
RNA interference-mediated silencing of X11alpha and X11beta attenuates amyloid beta-protein levels via differential effects on beta-amyloid precursor protein processing. J Biol Chem (2005) 1.11
HtrA2 regulates beta-amyloid precursor protein (APP) metabolism through endoplasmic reticulum-associated degradation. J Biol Chem (2007) 1.09
Protein aggregates and novel presenilin gene variants in idiopathic dilated cardiomyopathy. Circulation (2010) 1.08
GENETICS. The Human Variome Project. Science (2008) 1.07
Isoflurane decreases self-renewal capacity of rat cultured neural stem cells. Anesthesiology (2011) 1.06
Single-nucleotide polymorphism rs498055 on chromosome 10q24 is not associated with Alzheimer disease in two independent family samples. Am J Hum Genet (2006) 1.06
RNA interference silencing of the adaptor molecules ShcC and Fe65 differentially affect amyloid precursor protein processing and Abeta generation. J Biol Chem (2006) 1.05
The galvanization of beta-amyloid in Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 1.05
Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem (2005) 1.04
Alzheimer's disease-associated ubiquilin-1 regulates presenilin-1 accumulation and aggresome formation. Traffic (2011) 1.02
The zinc dyshomeostasis hypothesis of Alzheimer's disease. PLoS One (2012) 1.02
Loss of function of ATXN1 increases amyloid beta-protein levels by potentiating beta-secretase processing of beta-amyloid precursor protein. J Biol Chem (2010) 1.01
Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. Hum Mol Genet (2003) 1.01
Emerging role of Alzheimer's disease-associated ubiquilin-1 in protein aggregation. Biochem Soc Trans (2010) 1.00
Cerebrospinal fluid aβ to tau ratio and postoperative cognitive change. Ann Surg (2013) 0.99
Exploring candidate gene associations with neuropsychological performance. Am J Med Genet B Neuropsychiatr Genet (2007) 0.99
Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis. Exp Gerontol (2004) 0.98
Metal exposure and Alzheimer's pathogenesis. J Struct Biol (2006) 0.98
Insulin-degrading enzyme is genetically associated with Alzheimer's disease in the Finnish population. J Med Genet (2007) 0.98
Soluble γ-secretase modulators selectively inhibit the production of the 42-amino acid amyloid β peptide variant and augment the production of multiple carboxy-truncated amyloid β species. Biochemistry (2014) 0.98
Association of GSK3B with Alzheimer disease and frontotemporal dementia. Arch Neurol (2008) 0.98
Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and Aβ oligomerization. PLoS One (2011) 0.98
The role of the low-density lipoprotein receptor-related protein (LRP1) in Alzheimer's A beta generation: development of a cell-based model system. J Mol Neurosci (2002) 0.97
Alzheimer disease: New light on an old CLU. Nat Rev Neurol (2010) 0.97
Effects of RNAi-mediated silencing of PEN-2, APH-1a, and nicastrin on wild-type vs FAD mutant forms of presenilin 1. J Mol Neurosci (2005) 0.97
LRP-mediated clearance of Abeta is inhibited by KPI-containing isoforms of APP. Curr Alzheimer Res (2005) 0.97
Effects of ubiquilin 1 on the unfolded protein response. J Mol Neurosci (2008) 0.97
Spatial memory is intact in aged rats after propofol anesthesia. Anesth Analg (2008) 0.95
Age-dependent effect of apolipoprotein E4 on functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2010) 0.93